In this study, we utilized CBL-70Z, a well-characterized oncogenic CBL mutant lacking residues 366–382, and CBL-Y371S, a prevalent MDS/MPN CBL mutant, as E3-inactive CBL mutants to explore their oncogenic mechanism. This evidence concerns the gene CBL and myelodysplastic syndrome.